The combined use of mass drug administration and indoor residual spraying is the most effective way to reduce malaria prevalence in low malaria-endemic settings, and antibodies against PfGARP kill malaria-infected cells by inducing cell death.
An interview with Dr Melanie Renshaw, Chief Policy Officer of the RBM Partnership to End Malaria, to discuss progress against malaria, the funding gap and how access to core malaria interventions will be maintained during the COVID pandemic.
A summary of where we are in the fight against malaria and an overview of what more needs to be done.
Genetic variation would seem to have little impact on the success of gene drive interventions due to conserved Cas9 target sites in populations of Anopheles mosquitoes.
Results from the first human trial of the novel antimalarial drug SJ733 are published in The Lancet.
Enhancing antibody induction may improve the protective efficacy of RTS,S and researchers find that more gametocytes are produced when human infection is initiated by blood-stage parasites compared to mosquito bite.
The FDA issue an emergency use authorisation for the anti-malarial drug chloroquine, allowing for it to be used to treat certain hospitalised patients with COVID-19.
Scientists evaluate chloroquine as a potential treatment for the coronavirus and, as it continues to spread around the world, a report in The Lancet stresses the need for preparedness in malaria-endemic regions.
A protein called PIMMS43 enables the malaria parasite to evade the mosquito’s immune system and scientists describe a highly conserved protein in the malaria parasite that is essential for the invasion of red blood cells.
The global supply chain linked to deforestation leads to an increase in malaria prevalence and scientists identify the mechanism of action of clemastine, an antihistamine that inhibits multiple stages of the malaria parasite’s lifecycle.